EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Association of Acute Kidney Injury and Chronic Kidney Disease With Concentration‐To‐Dose Ratios of Midazolam and Its Main Metabolites in Critically Ill Adults

Kimberly Shudofsky iD, Johanna Abma, Johanna Driessen, Marielle Slikkerveer, Floris Vanmolkot, Paddy Janssen, Jos le Noble

Fundamental & Clinical Pharmacology · 2026-07 · 40 (4)

DOI: 10.1111/fcp.70108 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Fundamental & Clinical Pharmacology, online erschienen am 17.07.2026. Verfasst von Kimberly Shudofsky und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, VieCuri Medical Center, Venlo, the Netherlands. Hauptthemen laut MEDLINE: Midazolam, Acute Kidney Injury, Renal Insufficiency, Chronic, Hypnotics and Sedatives. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Midazolam (MDZ) is used for sedation in critically ill patients. Although previous studies have examined MDZ pharmacokinetics in ICU patients, the differential effects of acute kidney injury (AKI) and chronic kidney disease (CKD), particularly in cohorts including COVID‐19 and non‐COVID‐19 patients, remain insufficiently characterised.

Objectives

To investigate whether AKI and CKD are associated with dose‐normalised exposure of MDZ, 1‐hydroxy‐midazolam (1‐OH‐MDZ) and 1‐hydroxy‐midazolam glucuronide (1‐OH‐MDZ‐G) in critically ill adults.

Methods

In this retrospective observational study, ICU patients receiving continuous intravenous MDZ were included. Plasma concentrations of MDZ, 1‐OH‐MDZ and 1‐OH‐MDZ‐G were converted to concentration‐to‐dose (C/D) ratios. Cross‐sectional analysis used the first sample per patient; longitudinal analysis included all samples in GEE models. Analyses were adjusted for age, sex, BMI, COVID‐19 status, CYP3A4 inhibitor use, APACHE IV score, time since MDZ initiation and CRP.

Results

Forty‐seven patients contributed 137 samples. In the cross‐sectional analysis, C/D ratios of MDZ and 1‐OH‐MDZ did not differ between patients with and without AKI, whereas 1‐OH‐MDZ‐G C/D ratios were higher in AKI (median [IQR] 14.54 [6.14–26.20] vs. 4.53 [2.52–6.00]; p < 0.01). Longitudinal analysis showed that AKI ( β = 0.87), AKI Stage 1 ( β = 0.81), AKI Stages 2–3 ( β = 0.97) and CKD ( β = 0.72) were all significantly associated with higher 1‐OH‐MDZ‐G C/D ratios (all p ≤ 0.03). No significant associations were observed for MDZ or 1‐OH‐MDZ.

Conclusion

AKI and CKD are associated with accumulation of 1‐OH‐MDZ‐G in critically ill patients. Monitoring 1‐OH‐MDZ‐G may help identify patients at risk of prolonged sedation and adverse outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MidazolamAcute Kidney InjuryRenal Insufficiency, ChronicHypnotics and SedativesHumansFemaleMaleRetrospective StudiesCritical IllnessMiddle AgedAgedCross-Sectional StudiesIntensive Care UnitsDose-Response Relationship, Drug

Stichwörter der Autor:innen

acute kidney injurychronic kidney diseasecritically illmidazolamrenal clearance

Substanzen

MidazolamHypnotics and Sedatives1-hydroxymethylmidazolam

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, VieCuri Medical Center, Venlo, the Netherlands.
  • Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Centre+, Maastricht, the Netherlands.
  • Department of Clinical Pharmacy, Flevo Hospital, Almere, the Netherlands.
  • Department of Clinical Pharmacy, CARIM, the Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, the Netherlands.
  • Department of Internal Medicine, Maastricht University Medical Centre+, Maastricht, the Netherlands.

ORCID-Profile: Kimberly Shudofsky

Zitieren

APA

Shudofsky, K., Abma, J., Driessen, J., Slikkerveer, M., Vanmolkot, F., Janssen, P., & le Noble, J. (2026). Association of Acute Kidney Injury and Chronic Kidney Disease With Concentration‐To‐Dose Ratios of Midazolam and Its Main Metabolites in Critically Ill Adults. Fundamental & Clinical Pharmacology, 40(4). https://doi.org/10.1111/fcp.70108

Vancouver

Shudofsky K, Abma J, Driessen J, Slikkerveer M, Vanmolkot F, Janssen P, et al. Association of Acute Kidney Injury and Chronic Kidney Disease With Concentration‐To‐Dose Ratios of Midazolam and Its Main Metabolites in Critically Ill Adults. Fundamental & Clinical Pharmacology. 2026;40(4). doi:10.1111/fcp.70108

BibTeX
@article{Shudofsky2026,
  author = {Shudofsky, Kimberly and Abma, Johanna and Driessen, Johanna and Slikkerveer, Marielle and Vanmolkot, Floris and Janssen, Paddy and le Noble, Jos},
  title = {Association of Acute Kidney Injury and Chronic Kidney Disease With Concentration‐To‐Dose Ratios of Midazolam and Its Main Metabolites in Critically Ill Adults},
  journal = {Fundamental & Clinical Pharmacology},
  year = {2026},
  volume = {40},
  number = {4},
  doi = {10.1111/fcp.70108}
}
Kostenlos starten →